ClinicalTrials.gg
Drug

Pirfenidone clinical trials

Also written Esbriet and LYT-100.

studies test it
102
open now
17
in phase 3
20
first study started
1999

How each study uses pirfenidone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pirfenidone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Oct 2014 · ESBRIET · NDA 022535 (FDA, Drugs@FDA)
European Union
28 Feb 2011 · Esbriet · EMEA/H/C/002154 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pirfenidone
72
Deupirfenidone
5
kitoscell
3
Pirfenidone Oral Tablet
2
Pirfenidone (PFD)
2

Brand

Esbriet
17

Development codes

LYT-100
2
RO0220912
1

Studies by the year they started

101 studies that test it; most in 2017 (10); 1 more planned to start later

Studies that test pirfenidone, by start year
YearStudies
19991
20001
20012
20021
20032
20041
20052
20063
20081
20091
20112
20121
20133
20141
20157
20166
201710
20186
20198
20208
20219
20226
20235
20244
20255
20265

By phase

A phase 1/2 study counts in both.

Phase 1
24
Phase 2
53
Phase 3
20
Phase 4
11
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 36 · Other 66

Beijing Continent Pharmaceutical Co, Ltd. (6) · Hoffmann-La Roche (6) · Genentech, Inc. (6) · PureTech (5) · University of Guadalajara (4) · Boehringer Ingelheim (3) · National Cancer Institute (NCI) (3) · Qilu Hospital of Shandong University (2)

Often tested with

Tested in the same studies.

Nintedanib (11) · Nerandomilast (2) · Yinfenidone (2) · Methylprednisolone (2) · HRS-9813 (1) · Metformin (1) · Nalbuphine (1) · Silicon (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Pirfenidone is the comparator. A study of two new drugs counts under both.

  • 1AK3280 · Shanghai Ark Biopharmaceutical Co., Ltd. · next primary completion Sep 2028
  • 1Yinfenidone · Sunshine Lake Pharma Co., Ltd. · next primary completion Jan 2031
Reaching primary completion within a year · 4, 1 in phase 3

Studies that test pirfenidone, phase 3 first.

Studies

Open first, then newest update. How each study uses pirfenidone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 102

See all 102 studies that test pirfenidone →

Given beside what is tested · 5 — pirfenidone is usual care or a partner of the new treatment
As the comparator · 7 — what is tested is compared with pirfenidone

Codes

What other systems call pirfenidone · ClinicalTrials.gg INT003849

  • MeSH (NLM) C093844pirfenidoneConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) D7NLD2JX7UPIRFENIDONEConfirmed FDA, NLM, Wikidata
  • RxNorm 1592254Confirmed FDA, Wikidata
  • Wikidata Q2060696pirfenidoneConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C2635PirfenidoneOne source FDA
  • DrugBank DB04951One source Wikidata

Also registered as deupirfenidone (UNII 1QC36BHI6S).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.